retatrutide trial data just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Retatrutide FDA Approval Status 2026:

GLP-1 agonists like liraglutide (Victoza), lixisenatide (Adlyxin), dulaglutide (Trulicity), and semaglutide (Ozempic, Rybelsus) are commonly prescribed and continue to demonstrate benefits beyond just controlling blood sugar, including improvements in heart and metabolic health for some drugs

Affordability Ozempic is very expensive

In short: GLP-1/GIP therapies improve body composition , helping you lose fat while maintaining and often improving your lean-mass ratio and muscle function

Animal studies have raised concerns that medicines like Ozempic and Mounjaro may cause thyroid tumors, including cancer

These patient information resources are for clinicians to give to patients

PMID: 33755728